Send to

Choose Destination
Hum Genet. 2016 Sep;135(9):993-1010. doi: 10.1007/s00439-016-1696-0. Epub 2016 Jun 17.

Treating hemoglobinopathies using gene-correction approaches: promises and challenges.

Author information

Bioengineering Program, Clemson University and Medical University of South Carolina, Charleston, SC, 29425, USA.
Department of Bioengineering, Rice University, Houston, TX, 77030, USA.
Department of Bioengineering, Rice University, Houston, TX, 77030, USA.


Hemoglobinopathies are genetic disorders caused by aberrant hemoglobin expression or structure changes, resulting in severe mortality and health disparities worldwide. Sickle cell disease (SCD) and β-thalassemia, the most common forms of hemoglobinopathies, are typically treated using transfusions and pharmacological agents. Allogeneic hematopoietic stem cell transplantation is the only curative therapy, but has limited clinical applicability. Although gene therapy approaches have been proposed based on the insertion and forced expression of wild-type or anti-sickling β-globin variants, safety concerns may impede their clinical application. A novel curative approach is nuclease-based gene correction, which involves the application of precision genome-editing tools to correct the disease-causing mutation. This review describes the development and potential application of gene therapy and precision genome-editing approaches for treating SCD and β-thalassemia. The opportunities and challenges in advancing a curative therapy for hemoglobinopathies are also discussed.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center